Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Srividya, Arjuna"'
Autor:
Dechamma Pandyanda Nanjappa, Hanna De Saffel, Krithika Kalladka, Srividya Arjuna, Nishith Babu, Kishan Prasad, Patrick Sips, Anirban Chakraborty
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-9 (2023)
Abstract Poly (A)-specific ribonuclease (PARN) is the most important 3′–5′exonuclease involved in the process of deadenylation, the removal of poly (A) tails of mRNAs. Although PARN is primarily known for its role in mRNA stability, recent stud
Externí odkaz:
https://doaj.org/article/6cff2d0e82e44d0a84036be836486cfe
Publikováno v:
Monaldi Archives for Chest Disease (2021)
Tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) are effectively used in treatment of non-small cell lung cancer (NSCLC). Mutation profile of tyrosine kinase domain of EGFR determines the eligibility of the patients
Externí odkaz:
https://doaj.org/article/ae22c1af94224e9395a098f7df29af43
Autor:
Nishith Babu, Dechamma Pandyanda Nanjappa, Srividya Arjuna, V Rajesh, Vijith Shetty, Anirban Chakraborty
Publikováno v:
Journal of Clinical and Diagnostic Research, Vol 15, Iss 12, Pp 15-12 (2021)
Introduction: Ribonucleases (RNases) are enzymes involved in degradation of excess messenger Ribonucleic Acid (mRNA) and deadenylation of the poly(A) tail is the most common mechanism involved in mRNA degradation. Among the various RNases involve
Externí odkaz:
https://doaj.org/article/033910e3ee564bc39a81456a18e37759
Autor:
Nishith, Babu, Dechamma Pandyanda, Nanjappa, Sandra, Nazareth, Srividya, Arjuna, Anirban, Chakraborty
Publikováno v:
Asian Pacific Journal of Cancer Prevention. 23:207-215
Ribonucleases (RNases) is the collective term used for the group of enzymes that are involved in mRNA degradation. The shortening of the poly (A) tail through deadenylation is the preferred mechanism of degradation of most eukaryotic mRNAs and poly (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::685ce615426cfd760ac0f7e46a567a59
https://doi.org/10.31557/apjcp.2022.23.1.207
https://doi.org/10.31557/apjcp.2022.23.1.207
Publikováno v:
Monaldi Archives for Chest Disease (2021)
Tyrosine kinase inhibitors (TKIs) targeting epidermal growth factor receptor (EGFR) are effectively used in treatment of non-small cell lung cancer (NSCLC). Mutation profile of tyrosine kinase domain of EGFR determines the eligibility of the patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eeed1862d9b706d0bf885c1527e8c623
https://pubmed.ncbi.nlm.nih.gov/33960186
https://pubmed.ncbi.nlm.nih.gov/33960186
Autor:
Pandyanda Nanjappa Dechamma, Rajesh Venkataram, Anirban Chakraborty, Srividya Arjuna, Gunimala Chakraborty
Publikováno v:
Journal of Carcinogenesis
Journal of Carcinogenesis, Vol 19, Iss 1, Pp 3-3 (2020)
Journal of Carcinogenesis, Vol 19, Iss 1, Pp 3-3 (2020)
INTRODUCTION: Targeted therapy using specific inhibitors against tyrosine kinases (TKs) is a paradigm in non-small-cell lung cancer management. However, the success of TK inhibitor (TKI) therapy depends on certain activating or acquired mutations, wh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26ff227cbad8e679f43f8b0c4029d859
https://pubmed.ncbi.nlm.nih.gov/32684851
https://pubmed.ncbi.nlm.nih.gov/32684851
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.